Evaluation of a tumor marker gastrin-releasing peptide precursor in the patients with kidney injuries.

ABSTRACT: Gastrin-releasing peptide precursor (ProGRP) is a bioactive precursor of GRP and might play an important role as an emerging tumor marker in early cancer diagnosis. It might also be abnormal in the nonmalignant disease and renal function abnormalities. The present study was undertaken to investigate the changes of ProGRP levels in patients with kidney injuries, especially with chronic kidney disease (CKD), determine the upper reference intervals and clinical diagnostic value of ProGRP in CKD, and thus help oncologists in interpreting ProGRP levels and making clinical judgments of malignances. 676 individuals were enrolled in this cross-sectional study and divided into five groups: healthy control (n=194), CKD (n=272), nephrotic syndrome (NS) (n=137), antineutrophil cytoplasmic antibody (AN

SUBMITTER: Duan N 

PROVIDER: S-EPMC11897619 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature